$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
奥拉帕尼Olaparib维持治疗可改善患者的无进展生存期
2025-10-19 11:44:20
Check Details
奥拉帕尼的生存期数据和副作用有哪些?
2025-10-19 11:44:20
Check Details
治疗卵巢癌的新药PARP抑制剂尼拉帕尼!
2025-10-19 11:44:20
Check Details
靶向治疗卵巢癌的PARP抑制剂奥拉帕尼疗效怎么样?
2025-10-19 11:44:20
Check Details
卢卡帕利的适应症是什么?该怎么使用?
2025-10-19 11:44:20
Check Details
奥拉帕尼正确的使用方法以及推荐剂量是多少?
2025-10-19 11:44:20
Check Details
尼拉帕利副作用及处理
2025-10-19 11:44:20
Check Details
奥拉帕尼有哪些副作用?
2025-10-19 11:44:20
Check Details
卢卡帕利有副作用吗?疗效怎么样?
2025-10-19 11:44:20
Check Details
Lynib副作用及处理
2025-10-19 11:44:20
Check Details
Lynib副作用是什么?
2025-10-19 11:44:20
Check Details
尼拉帕利的副作用要怎么应对呢?
2025-10-19 11:44:20
Check Details
1
2
...
905
906
907
908
909
910
911
...
4162
4163
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Tamoxifen and Feeling Older: Managing Hot Flashes, Fatigue, and Skin Changes
2
FDA Approves Pembrolizumab for TMB-H Solid Tumors: Threshold ≥13 mut/Mb, KEYNOTE-158 Data
3
Capmatinib for METex14 NSCLC: Test First, Monitor Toxicity
4
Ribociclib Still Allows Recurrence: HR+/HER2- Adjuvant and Advanced Use
5
Tucatinib HER2 TKI: With Trastuzumab + Capecitabine, Diarrhea and Hepatotoxicity Monitoring
6
Pemigatinib for FGFR2-Rearranged Cholangiocarcinoma: Eligibility, Response Limits, Hyperphosphatemia and Ocular Monitoring
7
Cabozantinib with Aspirin: Additive Bleeding Risk, Do Not Stop Cardiac Aspirin Alone, Urgent Warning Signs
8
Zongertinib for HER2-Mutant NSCLC: First-Line ORR About 76%, Brain Metastases Controlled, Manage Diarrhea and Hepatotoxicity
9
Selpercatinib Traditional Approval for RET Fusion Solid Tumors: Weight-Based Adults, BSA-Based Pediatrics, Monitor Liver, BP, QT
10
Atezolizumab Plus mFOLFOX as Adjuvant Therapy for Stage III dMMR Colon Cancer: ATOMIC DFS HR 0.50
11
Tucatinib Plus Trastuzumab and Pertuzumab Maintenance in HER2-Positive Advanced Breast Cancer: HER2CLIMB-05 Median PFS 24.9 Months
12
Zenocutuzumab (Bizengri) for NRG1 Fusion Solid Tumors: HER2×HER3 Bispecific, 750mg Q2W, NSCLC/Pancreas/Cholangiocarcinoma